SNTI - Senti Biosciences Inc.
3.21
-0.130 -4.050%
Share volume: 20,000
Last Updated: 03-13-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$3.34
-0.13
-0.04%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-09-2023 | 08-11-2023 | 11-14-2023 | 03-21-2024 | 05-09-2024 | 08-13-2024 | 11-14-2024 | |
| Assets | ||||||||
| Total Assets | 161.425 M | 143.630 M | 131.766 M | 119.484 M | 102.185 M | 86.913 M | 57.721 M | |
| Current Assets | 80.511 M | 63.492 M | 79.007 M | 71.200 M | 55.666 M | 44.339 M | 17.384 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.614 M | 3.290 M | 20.957 M | 17.570 M | 14.020 M | 0.000 | 0.000 | |
| Short Term Investments | 3.614 M | 3.290 M | 20.957 M | 17.570 M | 14.020 M | 0.000 | 0.000 | |
| Total Receivables | 791.000 K | 567.000 K | 18.620 M | 17.704 M | 17.923 M | 0.000 | 0.000 | |
| Current Cash | 76.106 M | 59.635 M | 39.430 M | 35.926 M | 23.723 M | 15.860 M | 10.479 M | |
| Total Non-current Assets | 80.914 M | 80.138 M | 52.759 M | 48.284 M | 46.519 M | 0.000 | 0.000 | |
| Property Plant Equipment | 58.987 M | 58.940 M | 26.433 M | 25.338 M | 24.354 M | 23.253 M | 22.218 M | |
| Other Assets | 18.376 M | 17.862 M | 18.251 M | 17.608 M | 16.266 M | 19.321 M | 18.119 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 161.425 M | 143.630 M | 131.766 M | 119.484 M | 102.185 M | 86.913 M | 57.721 M | |
| Total liabilities | 49.085 M | 46.214 M | 48.830 M | 52.571 M | 46.091 M | 42.765 M | 41.727 M | |
| Total current liabilities | 12.866 M | 10.426 M | 10.114 M | 12.672 M | 9.609 M | 9.068 M | 9.064 M | |
| Accounts Payable | 2.582 M | 2.585 M | 1.991 M | 1.250 M | 1.624 M | 3.742 M | 3.771 M | |
| Other liabilities | 280.000 K | 99.000 K | 4.085 M | 6.361 M | 4.037 M | 33.697 M | 32.663 M | |
| Current long term debt | 2.151 M | 2.551 M | 2.682 M | 4.128 M | 4.278 M | 0.000 | 0.000 | |
| Long term debt | 35.939 M | 35.689 M | 34.631 M | 33.538 M | 32.445 M | 0.000 | 0.000 | |
| Other liabilities | 280.000 K | 99.000 K | 4.085 M | 6.361 M | 4.037 M | 33.697 M | 32.663 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 112.340 M | 97.416 M | 82.936 M | 66.913 M | 56.094 M | 44.148 M | 15.994 M | |
| Common stock | 44.071 M | 44.278 M | 44.473 M | 44.666 M | 45.709 M | 311.806 M | 312.518 M | |
| Retained earnings | -192.008 M | -210.705 M | -225.628 M | -244.344 M | -256.455 M | -267.658 M | -296.524 M |